3 research outputs found
Tarfia Faizullah, 37th Annual ODU Literary Festival
No full textTARFIA FAIZULLAH is the author of Seam (Southern Illinois University Press, 2014), winner of the Crab Orchard Series in Poetry First Book Award. Her poems appear in American Poetry Review, Ploughshares, The Missouri Review, The Southern Review, New England Review, and elsewhere. A Kundiman fellow, she received her MFA from Virginia Commonwealth University. Honors include a Ploughshares Cohen Award, a Fulbright fellowship and a Copper Nickel Poetry Prize. In fall 2014, she joins the University of Michigan as the Nicholas Delbanco Visiting Professor in Poetry
Registers of Illuminated Villages
No full textTarfia Faizullah’s highly anticipated second collection, Registers of Illuminated Villages, extends and transforms her powerful accounts of violence, war, and loss into poems of many forms and voices—elegies, outcries, self-portraits, and larger-scale confrontations with discrimination, family, and memory. One poem steps down the page like a Slinky; another poem responds to makeup homework completed in the summer of a childhood accident; other poems punctuate the collection with dark meditations on dissociation, discipline, defiance, and destiny; and the near-title poem, “Register of Eliminated Villages,” suggests illuminated texts, one a Qur’an in which the speaker’s name might be found, and the other a register of 397 villages destroyed in northern Iraq. Faizullah, the author of the award-winning collection Seam, is an essential poet, whose work only grows more urgent, beautiful, and—even in its unsparing brutality—full of love.
Tarfia Faizullah is the author of Seam, winner of a VIDA Award and a Great Lakes Colleges Association New Writers Award. She teaches at the University of Michigan and lives in Detroit
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
No full textBACKGROUND: Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia. Therapeutic responses across Afghanistan have not been evaluated in detail.
METHODS: Between July 2007 and February 2009, an open-label, randomized controlled trial of chloroquine and dihydroartemisinin-piperaquine in patients aged three months and over with slide-confirmed P. vivax mono-infections was conducted. Consistent with current national guidelines, primaquine was not administered. Subjects were followed up daily during the acute phase of illness (days 0-3) and weekly until day 56. The primary endpoint was the overall cumulative parasitological failure rate at day 56 after the start of treatment, with the hypothesis being that dihydroartemisinin-piperaquine was non-inferior compared to chloroquine (Delta = 5% difference in proportion of failures).
RESULTS: Of 2,182 individuals with positive blood films for P. vivax, 536 were enrolled in the trial. The day 28 cure rate was 100% in both treatment groups. Parasite clearance was more rapid with dihydroartemisinin-piperaquine than chloroquine. At day 56, there were more recurrent infections in the chloroquine arm (8.9%, 95% CI 6.0-13.1%) than the dihydroartemisinin-piperaquine arm (2.8%, 95% CI 1.4-5.8%), a difference in cumulative recurrence rate of 6.1% (2-sided 90%CI +2.6 to +9.7%). The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003). Multivariate analysis showed that a lower initial haemoglobin concentration was also independently associated with recurrence. Both regimens were well tolerated and no serious adverse events were reported.
CONCLUSIONS: Chloroquine remains an efficacious treatment for the treatment of vivax malaria in Afghanistan. In a setting where radical therapy cannot be administered, dihydroartemisinin-piperaquine provides additional benefit in terms of post-treatment prophylaxis, reducing the incidence of recurrence from 4-8 weeks after treatment
